Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Maria de las Mercedes Perez Rodriguez
Modality
protein_peptide
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02149823CT.gov Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Borderline Personality Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxytocin (this asset) | Maria de las Mercedes Perez Rodriguez | P1 | CC · 43 |
| Selegiline | Mood and Anxiety Research, Inc | P3 | BB |
| Citalopram | Columbia Northwest Pharmaceuticals | P2 | B |
| Teonanacatl | University of Chicago | P2 | B |
| Lithium, Elemental | Columbia Northwest Pharmaceuticals | P2 | B |
| Midazolam | Joshua Rosenblat | P2 | CCC |
| Escitalopram | University of Chicago | P2 | CCC |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Joshua Rosenblat | P2 | CCC |
| Sertraline | Yang I. Pachankis, PhD | Unk | D |
+1 more in the Borderline Personality Disorder cohort
Other indications for Oxytocin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prader-Willi Syndrome | — | P2/3 | BBB · 76 |
| Chronic Pain Syndrome | — | P4 | BB · 69 |
| Dystocia | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxytocin in Borderline Personality Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxytocin-borderline-personality-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →